Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Solar cell implant may restore some sight for the blind

Ophthalmologists at Rush University Medical Center implanted Artificial Silicon Retina (ASR) microchips in the eyes of five patients to treat vision loss caused by retinitis pigmentosa (RP). The implant is a silicon microchip 2mm in diameter and one-thousandth of an inch thick, less than the thickness of a human hair.

1 May 2005

Age-related macular degeneration is triggered, possibly by an infection

Age-related macular degeneration, the leading cause of blindness in the elderly, occurs when a common inherited gene variation is triggered, possibly by an infection, according to a new study led by researchers at Columbia University Medical Center and the University of Iowa, with an international research team.

1 May 2005

Research offers hope for treatment of age-related blindness

Rheumatoid arthritis patients treated with anti-inflammatory drugs are 10 times less likely to develop age-related macular degeneration (AMD), the most common form of blindness in people over 55, researchers at the University of British Columbia and University of Saskatchewan have found.

27 Apr 2005

Smoking doubles the risk of macular degeneration

Smoking doubles the risk of the progressive and irreversible eye condition, macular degeneration, and may account for almost 30,000 cases in the UK, suggests research in the British Journal of Ophthalmology.

19 Apr 2005

Bionic eyes from Stanford

Stanford physicists and eye doctors have teamed up to design a "bionic eye," of sorts. On Feb. 22 in the Journal of Neural Engineering, Daniel Palanker, Alexander Vankov and Phil Huie from the Department of Ophthalmology and the Hansen Experimental Physics Laboratory and Stephen Baccus from the Department of Neurobiology published a design of an optoelectronic retinal prosthesis system that can stimulate the retina with resolution corresponding to a visual acuity of 20/80

4 Apr 2005

Research tool for turning off genes may eventually have therapeutic application

A research team based at Massachusetts General Hospital (MGH) has identified 80 new genes essential to the process of RNA interference (RNAi), a powerful new research tool for inactivating genes in plants or animals.

28 Mar 2005

Compound found in broccoli is a powerful disease fighter

More than 300 scientific studies point to an antioxidant found in broccoli sprouts, sulforaphane glucosinolate (SGS), as a factor in preventing multiple diseases, including several types of cancer, high blood pressure, macular degeneration and stomach ulcers.

21 Mar 2005

Genes play a substantial role in the development of age-related macular degeneration

Genes play a substantial role in the development of age-related macular degeneration (AMD), one of the leading causes of irreversible blindness among older individuals, according to an article in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

14 Mar 2005

Gene identified that confers susceptibility to age-related macular degeneration

By combining the tools of high-throughput biology and statistical genetics, scientists at Rockefeller University, Yale University School of Public Health and the National Eye Institute have identified a gene that confers susceptibility to age-related macular degeneration (AMD), the most common cause of vision loss in the United Sates for those over 60.

14 Mar 2005

Gene for AMD has now been identified by researchers

Age-related macular degeneration (AMD) is a debilitating eye disease affecting about 15 million people in the United States.

13 Mar 2005

An apple a day keeps breast cancer away

An apple a day can help keep breast cancer away, according to a study in rats by food scientists at Cornell University.

1 Mar 2005

Encouraging results in wet age-related macular degeneration study

Novadaq Technologies has announced that Dr. Giovanni Staurenghi, (Associate Professor of Ophthalmology, Department of Otorhinolaryngological and Ophthalmological Science University of Milan, Italy), reported preliminary data on 24-patients in an on-going study using the Company's proprietary technology to treat wet Age-Related Macular Degeneration (AMD).

28 Feb 2005

Oak Ridge technology used to understand semiconductor defects helps people at risk of becoming blind

Millions of people at risk of becoming blind could one day be helped by an Oak Ridge National Laboratory technology originally intended to understand semiconductor defects.

10 Feb 2005

Macular degeneration patients benefit from self-management training

A 12-hour self-management program for individuals with advanced age-related macular degeneration (AMD) leads to lasting improvements in mood and function, especially in depressed patients, and decreases the development of clinical depression in AMD patients over time, according to a University of California, San Diego (UCSD) Shiley Eye Center study published in the January 2005 Archives of Ophthalmology.

10 Jan 2005

First program to apply RNA interference (RNAi) technology to asthma

Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.

7 Jan 2005

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.

30 Dec 2004

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004